Oliver Weirich

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

Jonathan I Silverberg, David Rosmarin, Thomas Bieber, Raj Chovatiya et autres

us, de, ca, cz, pl, au, hr, es, bg, gb (code pays fourni par la source)

Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, in Patients in Germany and Patients in the US: An Analysis of Two Phase 3 Trials

Zoe Diane Draelos, Janet C. DuBois, Oliver Weirich, Shraddha Bayar et autres

Background: A modified low-dose formulation of minocycline hydrochloride 40 mg (DFD-29; now approved as EmrosiTM) for treating inflammatory lesions of rosacea in the US. This pooled analysis of two phase 3 trials compared the efficacy of DFD-29 in patients in Germany and …

us, de (code pays fourni par la source)

Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites

Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu‐Huei Huang et autres

BACKGROUND: Plaque psoriasis involving high-impact sites is difficult to treat. Icotrokinra, a targeted oral peptide that selectively binds interleukin-23 receptors, is a new treatment being investigated for this condition. METHODS: This phase 3, double-blind, placebo-controlled trial randomly assigned participants 12 years of …

ca, us, tw, de, gb (code pays fourni par la source)

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea

Neal D Bhatia, JAMES Q. Del Rosso, Linda Stein Gold, Edward Lain et autres

Introduction: A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR). Objective: To determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR. Design, Setting, and Participants: …

us (code pays fourni par la source)

Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis

Andreas Pinter, Athanasios Tsianakas, Adina Eichner, Carle F. Paul et autres

INTRODUCTION: Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin inhibitor and is …

de (code pays fourni par la source)

Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment

Sascha Gerdes, Petra Staubach, Thomas Dirschka, Dieter Wetzel et autres

BACKGROUND: Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. OBJECTIVES: To evaluate the dose response, efficacy and safety of …

de, se (code pays fourni par la source)

Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial

Mauro Picardo, Carla Cardinali, M. La Plaça, Anita Lewartowska-Białek et autres

BACKGROUND: Preliminary in vitro and in vivo studies have supported the efficacy of the peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) for the treatment of acne-inducing sebocyte differentiation, improving sebum composition and controlling the inflammatory process. OBJECTIVES: To evaluate the efficacy and …

it, pl, de (code pays fourni par la source)